HSD17B13 and metabolic dysfunction-associated steatohepatitis: The results showed that HSD17B13 expression was no different between HBV infection and HBV un-infection in neither NASH nor in cirrhotic liver tissues (Figure 1C), though its expression was significantly up-regulated when compared to normal liver tissues (Figure 1C), suggesting that HSD17B13 expression is higher in the livers of patients with NAFLD, regardless of etiology.